Welcome to our dedicated page for Vascular Biogenics Ltd. news (Ticker: vblt), a resource for investors and traders seeking the latest updates and insights on Vascular Biogenics Ltd. stock.
Vascular Biogenics Ltd. (Nasdaq: VBLT), commonly known as VBL Therapeutics, is a leading biotechnology company headquartered at 6 Yonatan Netanyahu Street, Yehud, Center District, Israel. The company is dedicated to the discovery, development, and commercialization of innovative therapies for treating cancer and immune-inflammatory diseases. Its mission is to transform the standard of care in oncology through precision medicines.
Recently, VBL Therapeutics has made significant strides in its corporate journey. On August 14, 2023, the company announced its financial results for the second quarter ending June 30, 2023, and provided updates on its ongoing merger with Notable Labs, Inc. This merger is seen as a pivotal move, aiming to combine VBL's cutting-edge technologies with Notable's Predictive Precision Medicines Platform. The merger is anticipated to create a robust entity focused on developing a pipeline of clinical-stage precision medicines.
On September 6, 2023, the company's registration statement on Form S-4 was declared effective by the U.S. Securities and Exchange Commission (SEC), marking a critical milestone towards completing the merger. Following the approval from VBL’s shareholders at the annual and special meeting held on October 12, 2023, the merger is expected to close around October 16, 2023. Post-merger, VBL will be renamed 'Notable Labs, Ltd.' and will trade under the new symbol 'NTBL' on the Nasdaq Capital Market.
The merger with Notable Labs is expected to leverage Notable's technology to enhance VBL’s existing pipeline, offering a promising future for patients and shareholders alike. The combined organization aims to advance precision medicines that could significantly improve patient outcomes in oncology.
VBL Therapeutics (Nasdaq: VBLT) has expanded its OVAL Phase 3 study of VB-111, targeting platinum-resistant ovarian cancer, into Europe after enrolling the first patient. The study, involving over 200 participants across the U.S. and Israel, aims to establish VB-111 as a potential new standard of care in a challenging disease area. Interim results indicate a significant response rate of over 58%. The study received favorable recommendations from the Data Safety Monitoring Committee to proceed as planned, with the next review expected in Q1 2021.
VBL Therapeutics (Nasdaq: VBLT) announced that its Chairman, Dr. Bennett Shapiro, CEO Prof. Dror Harats, and other board members have purchased approximately 200,000 shares in open-market transactions between November 24 and December 3, 2020. This insider buying may signal confidence in the company's future prospects. VBL focuses on developing first-in-class treatments for cancer and immune/inflammatory conditions, with its leading candidate, VB-111, currently in a Phase 3 trial for platinum-resistant ovarian cancer.
VBL Therapeutics (Nasdaq: VBLT) announced progress in its OVAL Phase 3 study of VB-111 for platinum-resistant ovarian cancer, reporting a response rate of over 50% among approximately 200 enrolled patients. The company’s financial results for Q3 2020 show revenues of $193,000, up from $79,000 in Q3 2019, with a net loss of $5.8 million compared to $4.9 million the previous year. The cash position is strong, with $37.3 million on hand, expected to sustain operations through Q3 2022. VBL also initiated a Phase 2 study for VB-111 in colorectal cancer and reached alignment with the FDA for VB-601's clinical development.
VBL Therapeutics (Nasdaq: VBLT) announced that Prof. Dror Harats, M.D., CEO, will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 10:30 AM Eastern Time. The presentation format will be a fireside chat with analyst Swayampakula Ramakanth, Ph.D. A webcast will be available for live viewing and an archive of the event will be accessible on VBL's Investor Relations page. VBL Therapeutics specializes in developing innovative cancer treatments, including its lead candidate, ofranergene obadenovec (VB-111), which targets solid tumors.
VBL Therapeutics (Nasdaq: VBLT) will host a conference call on November 16, 2020, at 8:30 am ET to report third-quarter financial results and provide a corporate update. The company focuses on developing first-in-class treatments for cancer, with lead candidate Ofranergene obadenovec (VB-111) targeting solid tumors, currently in a Phase 3 trial for platinum-resistant ovarian cancer. VBL's technologies include gene-therapy and antibody platforms.
VBL Therapeutics (Nasdaq: VBLT) announced that the European Patent Office has granted Patent #3328401 for its anti-MOSPD2 monoclonal antibodies targeting various cancers. MOSPD2 is a protein linked to tumor metastasis, making it a promising target for cancer treatment. The patent protects VBL's innovation until at least July 2036. This milestone supports VBL's broader anti-cancer and inflammatory treatment strategies involving their VB-600 platform, which includes monoclonal antibodies and gene therapies.
VBL Therapeutics (Nasdaq: VBLT) announced the appointment of Marc Kozin as Vice Chairman of the Board, transitioning to Chairman in 2021. Current Chairman Bennett Shapiro will remain on the Board after stepping down. Kozin brings over three decades of biopharmaceutical experience, enhancing the company’s leadership as it advances its Phase 3 anti-cancer therapy, VB-111. Shapiro commended Kozin's qualifications for leading the company in fulfilling its mission to provide novel cancer treatments. VBL specializes in treatments for unmet needs in cancer and immune-related conditions.
VBL Therapeutics (Nasdaq: VBLT) announced the European Patent Office granted Patent #3328408 for its investigational anti-MOSPD2 monoclonal antibodies targeting inflammatory conditions. The patent protects the technology until at least July 2036. VBL has shown ex-vivo activity of these antibodies in multiple sclerosis patients and animal models for various inflammatory diseases. VBL plans to initiate a first-in-human study in the second half of 2021, having reached FDA alignment on the development path.
VBL Therapeutics (Nasdaq: VBLT) presented a corporate overview at the H. C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, highlighting progress in its OVAL pivotal study for VB-111 in ovarian cancer. Over a third of participants are enrolled, and interim analysis shows a high response rate consistent with earlier Phase 2 study results. The company focuses on developing innovative cancer treatments and continues to advance its clinical programs despite potential risks related to COVID-19 and financial sustainability.
VBL Therapeutics (Nasdaq: VBLT) revealed new ex-vivo data from its anti-MOSPD2 monoclonal antibodies for treating multiple sclerosis (MS). Presented at the MS Virtual 2020 conference, the study involved 33 patients, showing a remarkable 97% inhibition of monocyte migration, irrespective of disease severity or treatment. The company's lead candidate, VB-601, is advancing through IND-enabling studies with a first-in-human trial anticipated in the second half of 2021. These findings underscore the potential of VBL's proprietary MOSPD2-targeting approach in MS treatment.
FAQ
What is the market cap of Vascular Biogenics Ltd. (vblt)?
What does Vascular Biogenics Ltd. specialize in?
Where is Vascular Biogenics Ltd. located?
What recent corporate event did VBL announce?
What is the significance of the merger with Notable Labs?
When is the merger expected to be completed?
What will VBL be renamed after the merger?
What will be the new trading symbol for VBL after the merger?
What recent approvals did VBL receive for the merger?
Who is the CEO of VBL Therapeutics?
How will the merger benefit patients?
